Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
复制标题
DOI：
10.18632/oncotarget.15081
复制
发表时间：
2017-03-07
期刊：
影响因子：
--
通讯作者：
Yoshida M
中科院分区：
文献类型：
--
作者：
Nishiumi S;Kobayashi T;Kawana S;Unno Y;Sakai T;Okamoto K;Yamada Y;Sudo K;Yamaji T;Saito Y;Kanemitsu Y;Okita NT;Saito H;Tsugane S;Azuma T;Ojima N;Yoshida M
在发达国家，结直肠癌患者的数量一直在增加，结直肠癌是最常见的癌症死亡原因之一。为了提高结直肠癌患者的生活质量，有必要建立新的筛查方法，使其能够及早发现结直肠癌。我们用气相色谱/三重四极杆质谱仪对282例0/I/II期结直肠癌患者和291名健康志愿者的血浆样品进行代谢组学分析，试图确定0/I/II期结直肠癌的代谢物生物标志物。结直肠癌患者包括0期(N=79)、I期(N=80)和II期(N=123)，无侵袭和转移。我们的分析系统在血浆样本中检测到代谢物，29种代谢物水平在患者和健康志愿者之间存在显著差异(Bonferroni校正p=0.000781)。在此基础上，对各代谢物生物标志物进行多元Logistic回归分析，建立0/I/II期结直肠癌预测模型。该模型诊断0/I/II期结直肠癌的曲线下面积、灵敏度和特异度分别为0.996%、99.3%和93.8%。该模型对各疾病分期的敏感度和特异度均为90%，令人惊讶的是，其对0期疾病的敏感度、对0期疾病的特异度和对II期疾病的敏感度均为100%。我们的预测模型可以帮助早期发现结直肠癌，并有可能成为一种新的筛查方法，用于不涉及淋巴结或远处转移的结直肠癌病例。
In developed countries, the number of patients with colorectal cancer has been increasing, and colorectal cancer is one of the most common causes of cancer death. To improve the quality of life of colorectal cancer patients, it is necessary to establish novel screening methods that would allow early detection of colorectal cancer. We performed metabolome analysis of a plasma sample set from 282 stage 0/I/II colorectal cancer patients and 291 healthy volunteers using gas chromatography/triple-quadrupole mass spectrometry in an attempt to identify metabolite biomarkers of stage 0/I/II colorectal cancer. The colorectal cancer patients included patients with stage 0 (N=79), I (N=80), and II (N=123) in whom invasion and metastasis were absent. Our analytical system detected 64 metabolites in the plasma samples, and the levels of 29 metabolites differed significantly (Bonferroni-corrected p=0.000781) between the patients and healthy volunteers. Based on these results, a multiple logistic regression analysis of various metabolite biomarkers was carried out, and a stage 0/I/II colorectal cancer prediction model was established. The area under the curve, sensitivity, and specificity values of this model for detecting stage 0/I/II colorectal cancer were 0.996, 99.3%, and 93.8%, respectively. The model's sensitivity and specificity values for each disease stage were >90%, and surprisingly, its sensitivity for stage 0, specificity for stage 0, and sensitivity for stage II disease were all 100%. Our predictive model can aid early detection of colorectal cancer and has potential as a novel screening test for cases of colorectal cancer that do not involve lymph node or distant metastasis.